Broker downgrade: Is Incitec Pivot Ltd worth your investing dollars?

Incitec Pivot Ltd (ASX:IPL) slumps as analysts question its earnings.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Incitec Pivot Ltd's (ASX: IPL) shares crashed on Thursday following broker downgrades from leading investment banks Credit Suisse and UBS.

The broker downgrades follow competitor Orica Ltd's (ASX: ORI) disappointing half-year 2016 results reported in May. This sets up expectations that Incitec will disappoint when it reports earnings in November this year (due to market conditions).

Broker downgrades

As reported in  the Fairfax Press, Credit Suisse analysts believe the manufacturer of fertiliser and chemicals used in industrial and agricultural production faces a tight ammonia and phosphate market (Incitec's largest business unit), with supply-side capacity driving spot prices lower.

Credit Suisse forecasts supply to outstrip demand in 2017 and 2018, causing a market glut and squeezing Incitec's margins. Accordingly, it sees organic growth as an unlikely feature in the medium term.

UBS analysts paint a similar story, based on the assumption that spot fertiliser prices are maintained. It regards Incitec's ability to use free cash flows (based on current spot prices of ammonia and phosphate) as being unable to satisfy the widely expected $500 million buy-back later this year, without increasing debt levels.

As such, UBS downgraded its expectation of a buy-back to $200 million on conservative estimates and revised its price target to $3.10 (from $3.80).

Nevertheless, I remain upbeat about Incitec's prospects and think it's a buy for the following reasons.

Growth engine

Incitec is constructing a state-of-the-art ammonia production facility in Louisiana, U.S., which is expected to come online in the third quarter of this year.

The completion of the plant comes at a time when gas prices, which make up 75% of the cost of ammonia production, are hovering near all-time lows.

Although gas prices have rebounded slightly in recent months (and ammonia prices have moderated somewhat), analysts at Deutsche Bank believe the plant will generate earnings (EBITDA) of US$98 million in the 2017 financial year, targeting an internal rate of return of 15%. Any further depreciation of the Australian dollar against the U.S. dollar should increase the return from this project, boding well for results (and capital management).

Capital management

I believe Incitec's strength lies in the quality of its balance sheet.

Despite dwindling commodity prices, the market expects Incitec to conduct a buyback, placing it one step ahead of Rio Tinto Limited (ASX: RIO) and BHP Billiton Ltd (ASX: BHP) in my books (who both scrapped their progressive dividend policies in a similar scenario).

Moreover, even with its ongoing investment in the U.S. and decreased spot prices for its products, Incitec was able to slash net debt in 2015 to $1.3 billion using free cash flows. Analysts at Deutsche Bank expect this trend to continue, forecasting an impressive net debt/EBITDA ratio of 2.0x by the 2017 financial year.

Foolish takeaway

In my opinion, Thursday's slump in share price is driven by market sentiment and does not necessarily reflect management's long-term strategy of reinvesting in its core fertilisers businesses.

Incitec's strong balance sheet should see it through prolonged periods of lower commodity prices, whilst paying dividends and pursuing other capital management strategies. This, in my view, makes it a compelling investment today.

Motley Fool contributor Rachit Dudhwala has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »